Prevents organ rejection. ANDA 214283, held by Bpi Labs. Mycophenolate Mofetil Hydrochloride.
As of Nov 16, 2026, ANDA 214283 (Mycophenolate Mofetil Hydrochloride), held by Bpi Labs, was first approved by FDA on Jun 1, 2023, with 1 approved supplement and 0 published complete response letters.
Mycophenolate Mofetil (MMF) is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants. Mycophenolate Mofetil is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 1, 2023 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mycophenolate Mofetil Hydrochloride500MG/VIAL · injectable;injection | Mycophenolate Mofetil Hydrochloride | Rx |
| Jul 29, 2026 | Supplement 3REMS | Approved | None posted |
| Jun 1, 2023 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters